source
- Big pharma say they will stop opening new trial sites in Xinjiang and Chinese military hospitalsSeveral of the world’s largest pharmaceutical companies told a U.S. House Select Committee on China that they will not start new clinical trial sites in the Xinjiang region of China or at hospitals…
- FDA approves treatments for four rare diseases; Pfizer inks $2.6 billion China licensing deal for CAR‑T therapyThe U.S. Food and Drug Administration has granted approval for drugs targeting four distinct rare diseases, expanding therapeutic options for patients with limited treatment choices. In a separate…